AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease

被引:35
作者
Prasad, Kailash [1 ]
Dhar, Indu [1 ]
Zhou, Qifeng [2 ,3 ]
Elmoselhi, Hamdi [2 ,3 ]
Shoker, Muhammad [1 ]
Shoker, Ahmed [2 ,3 ]
机构
[1] Univ Saskatchewan, Dept Physiol, Coll Med, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada
[2] Univ Saskatchewan, Coll Med, Dept Med, Saskatoon, SK, Canada
[3] Univ Saskatchewan, Royal Univ Hosp, Saskatoon, SK, Canada
关键词
Advanced glycation end products (AGEs); Soluble receptors for AGE; sRAGE; esRAGE; cRAGE; AGEs/sRAGE; Inflammation; End-stage renal disease; CIRCULATING SOLUBLE RECEPTOR; CHRONIC KIDNEY-DISEASE; SERUM-LEVELS; CARDIOVASCULAR-DISEASE; PLASMA-LEVELS; PRODUCTS; ATHEROSCLEROSIS; RAGE; ASSOCIATION; AGE;
D O I
10.1007/s11010-016-2829-4
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Interaction of advanced glycation end products (AGEs) with its cell-bound receptor (RAGE) results in cell dysfunction through activation of nuclear factor kappa-B, increase in expression and release of inflammatory cytokines, and generation of oxygen radicals. Circulating soluble receptors, soluble receptor (sRAGE), endogenous secretory receptor (esRAGE) and cleaved receptor (cRGAE) act as decoy for RAGE ligands and thus have cytoprotective effects. Low levels of sRAGE and esRAGE have been proposed as biomarkers for many diseases. However sRAGE and esRAGE levels are elevated in diabetes and chronic renal diseases and still tissue injury occurs. It is possible that increases in levels of AGEs are greater than increases in the levels of soluble receptors in these two diseases. Some new parameters have to be used which could be an universal biomarkers for cell dysfunction. It is hypothesized that increases in serum levels of AGEs are greater than the increases in the soluble receptors, and that the levels of AGEs is correlated with soluble receptors and that the ratios of AGEs/sRAGE, AGEs/esRAGE and AGEs/cRAGE are elevated in patients with end-stage renal disease (ESRD) and would serve as an universal risk marker for ESRD. The study subject comprised of 88 patients with ESRD and 20 healthy controls. AGEs, sRAGE and esRAGE were measured using commercially available enzyme linked immune assay kits. cRAGE was calculated by subtracting esRAGE from sRAGE. The data show that the serum levels of AGEs, sRAGE, cRAGE are elevated and that the elevation of AGEs was greater than those of soluble receptors. The ratios of AGEs/sRAGE, AGEs/esRAGE and AGEs/cRAGE were elevated and the elevation was similar in AGEs/sRAGE and AGEs/cRAGE but greater than AGEs/esRAGE. The sensitivity, specificity, accuracy, and positive and negative predictive value of AGEs/sRAGE and AGEs/cRAGE were 86.36 and 84.88 %, 86.36 and 80.95 %, 0.98 and 0.905, 96.2 and 94.8 %, and 61.29 and 56.67 % respectively. There was a positive correlation of sRAGE with esRAGE and cRAGE, and AGEs with esRAGE; and negative correlation between sRAGE and AGEs/sRAGE, esRAGE and AGES/esRAGE, and cRAGE and AGES/cRAGE. In conclusion, AGEs/sRAGE, AGEs/cRAGE and AGEs/esRAGE may serve as universal risk biomarkers for ESRD and that AGEs/sRAGE and AGEs/cRAGE are better risk biomarkers than AGEs/esRAGE.
引用
收藏
页码:105 / 114
页数:10
相关论文
共 50 条
  • [31] Adiponectin and end-stage renal disease
    Markaki A.
    Psylinakis E.
    Spyridaki A.
    Hormones, 2016, 15 (3) : 345 - 354
  • [32] Red blood cell abnormalities and the pathogenesis of anemia in end-stage renal disease
    Georgatzakou, Hara T.
    Antonelou, Marianna H.
    Papassideri, Issidora S.
    Kriebardis, Anastasios G.
    PROTEOMICS CLINICAL APPLICATIONS, 2016, 10 (08) : 778 - 790
  • [33] Thyroid disease in end-stage renal disease
    Rhee, Connie M.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2019, 28 (06) : 621 - 630
  • [34] Chronic inflammation in end-stage renal disease and dialysis
    Cobo, Gabriela
    Lindholm, Bengt
    Stenvinkel, Peter
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 : 35 - 40
  • [35] Chronic Inflammation and Coronary Atherosclerosis in Patients with End-Stage Renal Disease
    Nusair, Maen B.
    Rajpurohit, Naveen
    Alpert, Martin A.
    CARDIORENAL MEDICINE, 2012, 2 (02) : 117 - 124
  • [36] Perioperative Management of Patients With End-Stage Renal Disease
    Kanda, Hirotsugu
    Hirasaki, Yuji
    Iida, Takafumi
    Kanao-Kanda, Megumi
    Toyama, Yuki
    Chiba, Takashi
    Kunisawa, Takayuki
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2017, 31 (06) : 2251 - 2267
  • [37] End-Stage Renal Disease, Inflammation and Cardiovascular Outcomes
    Dai, Lu
    Golembiewska, Edyta
    Lindholm, Bengt
    Stenvinkel, Peter
    EXPANDED HEMODIALYSIS: INNOVATIVE CLINICAL APPROACH IN DIALYSIS, 2017, 191 : 32 - 43
  • [38] UMOD as a susceptibility gene for end-stage renal disease
    Reznichenko, Anna
    Boeger, Carsten A.
    Snieder, Harold
    van den Born, Jacob
    de Borst, Martin H.
    Damman, Jeffrey
    van Dijk, Marcory C. R. F.
    van Goor, Harry
    Hepkema, Bouke G.
    Hillebrands, Jan-Luuk
    Leuvenink, Henri G. D.
    Niesing, Jan
    Bakker, Stephan J. L.
    Seelen, Marc
    Navis, Gerjan
    BMC MEDICAL GENETICS, 2012, 13
  • [39] Predictors of End-stage Renal Disease in the Urban Poor
    Hall, Yoshio N.
    Choi, Andy I.
    Xu, Ping
    Smith, Nicholas L.
    Boyko, Edward J.
    JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED, 2013, 24 (04) : 1686 - 1700
  • [40] Proteinuria and the risk of developing end-stage renal disease
    Iseki, K
    Ikemiya, Y
    Iseki, C
    Takishita, S
    KIDNEY INTERNATIONAL, 2003, 63 (04) : 1468 - 1474